This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
AI simulated cell company Turbine is just one of many digital drug discovery firms on the rise in Hungary. We speak to the company’s CEO and co-founder, Szabolcs Nagy, to find out why moving beyond traditional biotech drug development is a good fit for the country’s ecosystem. Hungarian company, Turbine, is taking an alternative approach to the standard biotech drug development model with its AI-based simulated cell technology, which helps the bulk of preclinical drug discovery take place digita
Artificial intelligence software company Thirona has released PRAGMA-AI, technology that automates and accelerates CT scans in cystic fibrosis analysis.
Amlodipine is one of the most commonly prescribed drugs in the UK and the most prescribed high blood pressure ( BP ) medication. When patients are diagnosed with high blood pressure and a drug is recommended, amlodipine may be the first choice, but not always. Taking any drugs comes with a risk of side effects, with amlodipine associated with few common side effects.
Until the COVID-19 pandemic struck the world in early 2020, pharma had been pretty resistant to the idea of involving the end-customer, or the patient, into their business models. COVID-19 not only left pharma no choice but to take this challenge head on, it also paved the way for pharma to build extensive awareness of their brands, as several big names have been in the spotlight in the fight against COVID-19.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Two antibodies targeting different parts of the COVID-19 virus spike protein, from Eli Lilly and GlaxoSmithKline/Vir Biotech, can cut viral load dramatically within a week. . The BLAZE-4 trial found that co-administration of Lilly’s bamlanivimab – already granted emergency approval as a COVID-19 treatment – and GSK/Vir’s experimental antibody VIR-7831 reduced virus levels by 70% after seven days compared to placebo in people with mild or moderate COVID-19 symptoms.
The advanced biotech analysis company is harnessing the power of a formidable supercomputer to discover potential treatments for the virus and mutations.
Christian Schena brings prolific relationship-building, sales consulting, lead generation, and business development experience to the firm. Boston, Mass. March 30, 2021 — Fuld + Company, a global competitive strategy consultancy, today announced the recent appointment of Christian Schena as Senior Director of Sales. In this role, he will leverage decades of experience in the sales consulting space to develop customized solutions for clients of Fuld + Company that are critical for market competit
59
59
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Christian Schena brings prolific relationship-building, sales consulting, lead generation, and business development experience to the firm. Boston, Mass. March 30, 2021 — Fuld + Company, a global competitive strategy consultancy, today announced the recent appointment of Christian Schena as Senior Director of Sales. In this role, he will leverage decades of experience in the sales consulting space to develop customized solutions for clients of Fuld + Company that are critical for market competit
The AI in Healthcare Virtual Summit focused on AI methods and tools that are set to transform healthcare, medicine, and diagnostics along with the latest applications within the industry. . Here are some key sessions during the summit that discussed machine learning for antibiotic discovery, creating personalized neuro medicine using AI and brain modelling, and deep learning for biomedical imaging.
Germany and Canada have both slapped restrictions on the AstraZeneca vaccine, recommending its use only in older patients, because of concerns over a link with blood clots. The moves come after the country’s medicines regulator found 31 cases of a rare type of blood clot known as cerebral venous sinus thrombosis (CVST) in people who had received the vaccine produced by AZ.
A representative of the rare-disease specialist firm outlines the unique obstacles of orphan CNS disease research, and how professionals can overcome them.
Azelis, an innovation service provider, is excited to release its sustainability strategy, ‘Action 2025’, reinforcing its commitment to become the world-leading provider of sustainable solutions and services in the specialty chemicals and food ingredients distribution industry. Through its sustainability program and strategy, Azelis wants to turn the sustainability aspirations of its principals and customers into innovative sustainable solutions.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
The virtual NextGen Pharma Content Summit on March 23-24, 2021 focused on the importance of creating personalized and genuine content for their customers in the right place and at the right time. Sessions throughout the summit touched on the many ways that companies can convey the right message to their customers. By creating personalized and meaningful messages to customers, companies can build trust and earn brand loyalty. .
Akili has published data backing the efficacy of its childhood attention-deficit hyperactivity disorder (ADHD) video game therapy EndeavorRx in the peer-review journal Nature Digital Medicine. . The results come from the STARS-Adjunct trial, an open-label study of EndeavorRx (AKL-T01) that supported approval of the app and video game combination in the US and Europe last year.
An expert speaking at the April 6 Clinical Development Innovations event will discuss an app that matches patients with clinical research opportunities.
Informa Markets is launching an annual dedicated online platform for pharma in May (17-28th), CPhI Discover – designed to encourage suppliers and customers to source, meet and discover – providing the industry with a new synergistic offering to sit alongside CPhI’s portfolio of in person events. In the last year, the pharma industry has adapted its approach to meeting new partners and existing customers, with wider pools of suppliers now needed, putting greater pressure on resources to find and
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
In the latest episode of the podcast Dominic Tyer speaks with GlaxoSmithKline’s Philip Cruz about the discovery and commercialisation of new vaccines in the light of the pandemic. Philip who is vaccines medical director for the UK and Ireland, and a paediatrician by training, tackles the clear pre- and post-COVID differentiation seen in approaches to vaccines.
According to a Veeva Systems survey, contract research organizations are working to ensure clinical trials keep going during the COVID-19 era and beyond.
Sacubitril/valsartan (ARNI) is getting more attention in the guidelines with regards to its use in heart failure (specifically HFrEF). Many patients are already on an ACE and making the transition from an ACE inhibitor to an ARNI is likely something you will come across. In clinical practice, there is a significant risk for angioedema when […].
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
The way NICE reviews new medicines is about to go through its biggest change in years – but what do the proposals mean for the future of drug development in the UK? Amanda Barrell spoke to Dr Paul Catchpole, director of value and access policy at the ABPI, to find out. From COVID-19 and Brexit, to the emergence of patient-centric drug development and personalised medicine, the life sciences sector has experienced a complete transformation in recent years.
This monthâs hires, promotions, acquisitions and other notable news includes Ajinomoto, Medable, Charles River, Immunai, AstraZeneca and other top firms.
I recently had the opportunity to attend the Sex & Gender 101 webinar designed to help anyone in the healthcare field learn more about creating trans inclusive care. It is crucial to create an environment that is inclusive because trans people – especially trans people of color – face many barriers to healthcare. We have all had doctor’s appointments where we were required to fill out a form and check one of two boxes to describe our gender: male or female.
Incentivising people with KPI-linked bonuses is nothing new. Especially in commercial roles it has long been standard. The issue with KPIs is they can be very ineffective. If clearly defined they will get you results, but if not, they can just reinforce the wrong behaviours. The difficulty is to define the right ones. Bottomline is that KPI-based incentives will hardly ever create the behaviour that you want and in some of the worst examples have caused a disaster like the financial crisis in 20
The FDA has approved Bristol-Myers Squibb’s Abecma (idecabtagene vicleucel) for multiple myeloma, the first cell therapy to treat the disease. Abecma’s review was delayed after the FDA rejected a first filing in May last year, but it’s hoped that the drug could be a significant step forward in the treatment of this incurable condition. It is a CAR-T (chimeric antigen receptor T-cell) therapy, where a patient’s own T-cells are harvested, genetically modified and then reinjected to fight the cance
Pharma is moving to a new era of radically new therapies, presenting unexpected and difficult challenges. Such interventions take the need for robust value claims to a completely different level, with important implications for the evidence companies need to collect, and how they collect and communicate it. Chris Gray leads Innovation and Ventures for Adelphi’s Healthcare Communications agencies, whose long-running Renaissance series has been discussing the implications of ‘ transformational va
All Nippon Airways (ANA) has begun a trial of its CommonPass app showing a traveller’s COVID-19 status at Tokyo’s Haneda Airport. It’s part of efforts by the global travel industry to make cross-border travel easier and safer and is one of several digital health passports being trialled around the world. The idea is to provide an accurate but fast way of ensuring passengers are safe to travel and prevent the spread of COVID-19 and potential variants.
VMLY&Rx, a comms agency dedicated to prescription pharmaceutical companies who are researching and developing breakthrough therapies, has hired Nichole Davies as global chief strategy officer. . Davies will lead a new global strategic practice to deliver and enable connected health strategies for clients. The team comprises specialists across a wide range of strategic expertise including brand, activation, innovation and medical.
The UK’s cost-effectiveness agency NICE has recommended that Sobi’s Kineret can be used to treat NHS patients with Still’s disease, a rare form of arthritis affecting children and adults. The final guidance concludes that interleukin-1 receptor antagonist Kineret (anakinra) can be used as a treatment for two forms of Still’s, namely systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD).
With the focus on COVID-19 over the last year it’s easy to forget another deadly pandemic caused by antimicrobial resistance (AMR), which could lead to the most innocuous of infections becoming life threatening. The Novo Holding REPAIR Impact Fund is hoping to change this with its latest call for investment proposals to fight AMR. While there have been huge strides in treatments for cancer and other diseases in the last few decades, research into new antibiotics has been almost stagnant as big p
The FDA has approved Sanofi’s Sarclisa (isatuximab) in combination with a new chemotherapy regimen for advanced multiple myeloma, building on a first approval last year. This label extension covers use of Sarclisa plus carfilzomib and dexamethasone for adults with relapsed or refractory multiple myeloma, who have received one to three previous therapy lines.
Amgen has announced its second acquisition in the space of a month, snapping up Rodeo Therapeutics and its potential tissue repair drugs in a deal worth up to $721 million. Rodeo is a privately held biopharmaceutical company based in Seattle that develops small-molecule therapies designed to promote regeneration and repair of several tissues and could be used to treat the fatal lung scarring disease idiopathic pulmonary fibrosis (IPF).
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
123 
Let's personalize your content